solifenacin succinate has been researched along with oxotremorine m in 1 studies
| Studies (solifenacin succinate) | Trials (solifenacin succinate) | Recent Studies (post-2010) (solifenacin succinate) | Studies (oxotremorine m) | Trials (oxotremorine m) | Recent Studies (post-2010) (oxotremorine m) |
|---|---|---|---|---|---|
| 522 | 194 | 343 | 186 | 0 | 35 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, T; Kawashima, K | 1 |
1 other study(ies) available for solifenacin succinate and oxotremorine m
| Article | Year |
|---|---|
YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells.
Topics: Calcium Signaling; Cells, Cultured; Genes, fos; Humans; Isoquinolines; Muscarinic Antagonists; Oxotremorine; Quinuclidines; Receptor, Muscarinic M3; Receptors, Muscarinic; RNA, Messenger; Solifenacin Succinate; T-Lymphocytes; Tetrahydroisoquinolines | 2000 |